Home About

TL;DR CNBC


Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma - TL;DR CNBC

Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma

Publishing timestamp: 2023-12-20 07:00:01


Summary

Drugmakers are ending the year with historic firsts that will shape the pharmaceutical industry in the future. COVID vaccines and treatments saw a decline in demand, while attention shifted to weight loss medications and new Alzheimer's drugs. The weight loss drug market has become a gold rush, with Novo Nordisk and Eli Lilly leading the way. The approval of the first-ever Alzheimer's treatment and the rollout of vaccines against respiratory syncytial virus were significant milestones. However, the COVID product market saw a steep drop in demand as the world emerged from the pandemic. The pharmaceutical industry also faced challenges with the new Medicare drug price negotiations.


Sentiment: MIXED

Tickers: 4523.T-JP,  JNJ,  PFE,  BMY,  MRK,  AZN-GB,  LLY,  AMGN,  NOVO.B-DK,  BIIB, 

Keywords: biogen inc,  pfizer inc,  united states,  biotech and pharmaceuticals,  novo nordisk a/s,  amgen inc,  business news,  business,  eisai co ltd,  pharmaceuticals,  health care industry,  eli lilly and co,  biotechnology, 

Source: https://www.cnbc.com/2023/12/20/weight-loss-drugs-covid-downturn-pharma-had-a-year-full-of-firsts.html


Developed by Leo Phan